# A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

> **NCT03854227** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 54 (actual)

## Conditions studied

- Advanced Solid Tumors
- Metastatic Solid Tumors

## Interventions

- **DRUG:** PF-06939999 dose escalation
- **DRUG:** PF-06939999 monotherapy
- **DRUG:** PF-06939999 in combination with docetaxel

## Key facts

- **NCT ID:** NCT03854227
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-14
- **Primary completion:** 2022-04-27
- **Final completion:** 2022-04-27
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** The study has been terminated based on a strategic evaluation within the current Pfizer oncology portfolio. This decision is not due to any safety concerns or requests from any regulatory authorities.
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03854227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03854227, "A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03854227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*